Former global product manager at Illumina Inc
- Recent developments and implications following Illumina's (NASDAQ: ILMN) win in the BGI Genomics (SHE: 300676) patent infringement case over its proprietary two-colour sequencing-by-synthesis chemistry
- Market dynamic implications in sequencing prices
- Sequencing industry update across long-read and short-read, and M&A overview
- 2022 outlook and growth expectations
Gain access to Premium Content
Submit your details to access up to 5 Forum Transcripts or to request a complimentary one week trial.